These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 34169728)

  • 1. Rapid structure-based identification of potential SARS-CoV-2 main protease inhibitors.
    Sobhia ME; Kumar GS; Sivangula S; Ghosh K; Singh H; Haokip T; Gibson J
    Future Med Chem; 2021 Sep; 13(17):1435-1450. PubMed ID: 34169728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
    Isgrò C; Sardanelli AM; Palese LL
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
    Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
    Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
    Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
    Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
    Sardanelli AM; Isgrò C; Palese LL
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
    Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
    Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
    Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
    Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy.
    T MK; K R; James N; V S; K R
    Biotechnol Appl Biochem; 2021 Aug; 68(4):712-725. PubMed ID: 33797130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 M
    Peralta-Moreno MN; Mena Y; Ortega-Alarcon D; Jimenez-Alesanco A; Vega S; Abian O; Velazquez-Campoy A; Thomson TM; Pinto M; Granadino-Roldán JM; Santos Tomas M; Perez JJ; Rubio-Martinez J
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docking Paradigm in Drug Design.
    Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV
    Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
    Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
    Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
    Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS
    Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.